Interactive discussions - GLP-1 receptor agonists and CV risk management in type 2 diabetes: a new treatment paradigm?
Topic:
Diabetes, dysglycaemia and metabolic syndrome
Speaker:
Professor L. Ryden (Stockholm, SE)
Doctor M. Husain (Toronto, CA)
Professor M. Pfeffer (Boston, US)
Sponsored by Novo Nordisk
Event:
ESC Congress 2017
Congress Presentation
About the speakers
Professor Lars Ryden
Karolinska Institute, Stockholm (Sweden)
37
presentations
1
follower
Doctor Mansoor Husain
University of Toronto, Toronto (Canada)
7
presentations
2
followers
Professor Marc Pfeffer
Brigham And Women'S Hospital, Harvard Medical School, Boston (United States of America)
27
presentations
1
follower
3 more presentations in this session
Introduction - GLP-1 receptor agonists and CV risk management in type 2 diabetes: a new treatment paradigm?
Speaker: Professor L. Ryden (Stockholm, SE)
Results from the LEADER cardiovascular outcomes trial.
Speaker: Doctor M. Husain (Toronto, CA)
Translating trials into practice – Clinical implications .
Speaker: Professor M. Pfeffer (Boston, US)
Access the full session
GLP-1 receptor agonists and cardiovascular risk management in type 2 diabetes: a new treatment paradigm?
Speakers:
Professor L. Ryden, Doctor M. Husain, Professor M. Pfeffer, Professor L. Ryden, Doctor M. Husain...
About the event
ESC 365 is supported by
